Insys Therapeutics, Inc.
INSY
INSY was delisted on the 18th of June, 2019.
16 hedge funds and large institutions have $52K invested in Insys Therapeutics, Inc. in 2019 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 82 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
84% less funds holding
Funds holding: 98 → 16 (-82)
95% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 82
100% less capital invested
Capital invested by funds: $51.6M → $52K (-$51.6M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KBC Group
Brussels,
Belgium
|
+$142K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
+$28.3K |
| 3 |
AG
Aperio Group
Sausalito,
California
|
+$4.03K |
| 4 |
AF
Advisornet Financial
Minnetonka,
Minnesota
|
+$270 |
| 5 |
HNB
Huntington National Bank
Columbus,
Ohio
|
+$3 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$12.8M |
| 2 |
BlackRock
New York
|
-$11.9M |
| 3 |
Millennium Management
New York
|
-$3.75M |
| 4 |
Renaissance Technologies
New York
|
-$2.65M |
| 5 |
State Street
Boston,
Massachusetts
|
-$2.32M |
INSY Hedge Fund Activity: Q2 2019 in Review
16 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q2 2019, worth a combined $52K — down 100% from $51.6M a quarter earlier.
Sellers outnumbered buyers: 82 funds closed out of INSY and 4 opened new positions — a net loss of 78 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was KBC Group, opening a new position worth an estimated $142K. The largest seller was Vanguard Group, exiting entirely with an estimated $12.8M sold.
- 16 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q2 2019, down from 98 in Q1 2019.
- Funds reported $52K of Insys Therapeutics, Inc. stock for Q2 2019, down 100% quarter-over-quarter.
- 4 funds opened new Insys Therapeutics, Inc. positions in Q2 2019 and 82 closed out, a net change of -78 holders.
- The largest Insys Therapeutics, Inc. buyer in Q2 2019 was KBC Group, an estimated $142K added.
- The largest Insys Therapeutics, Inc. seller in Q2 2019 was Vanguard Group, an estimated $12.8M sold.
Based on aggregated 13F filings for Q2 2019.